March 11, 2019 06:31 AM EDTUpdated May 26, 08:50 PM

Early data snapshots of Axovant's gene therapies for Parkinson's, Tay Sachs appear promising

Natalie Grover

Reporter

Following the collapse of its neuro-focused strategy, Axovant’s foray into gene therapies — with their potential for one-shot, long-term cures — has generated considerable interest. On …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Early data snapshots of Axovant's gene therapies for Parkinson's, Tay Sachs appear promising

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ear­ly da­ta snap­shots of Ax­o­van­t's gene ther­a­pies for Parkin­son's, Tay Sachs ap­pear promis­ing

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Early data snapshots of Axovant's gene therapies for Parkinson's, Tay Sachs appear promising